Organizing Pneumonia Resulting from Rituximab
Wang Chunhui,Xu Qing,Wu Wei,Li Xiaoyu,Lyu Qianzhou
DOI: https://doi.org/10.3760/cma.j.issn.1008-5734.2018.04.018
2018-01-01
Abstract:A 15-year-old boy with diffuse large B cell lymphoma received treatment with a R-CHOP chemotherapy regimen consisting of rituximab,cyclophosphamide,epirubicin,vincristine and prednisone. During the second cycle of chemotherapy,on day 24 after intravenous infusion of rituximab 600 mg,he developed cough and expectoration and his symptoms did not relieve after 2 weeks of treatment with ceftazidime. High resolution CT (HRCT)of the chest showed air bronchogram and mottling in his left upper lung and right lower lung,and inflammatory consolidation was considered. After receiving treatment with biapenem and azithromycin,his symptoms,inflammatory indices,and imaging findings did not significantly improve. According to the temporal correlation as well as pathological and etiological examination results, interstitial pneumonia and cancerous obstructive pneumonia associated with pulmonary infection or connective tissue disease were excluded,and organizing pneumonia induced by rituximab was considered. Rituximab was stopped and replaced by a CHOP chemotherapy regimen. In addition,antibacterial drugs were withdrawn and oral prednisolone 15 mg thrice daily was given. Thirty days later,the patient's cough slightly relieved. However,when the dose of glucocorticoid was reduced to 15 mg/d,his cough and expectoration was slightly aggravated. Subsequently,the dose of prednisolone was increased to 40 mg/d,and 42 days later,was decreased to 20 mg/d. Eighty eight days later,the patient's cough significantly improved,HRCT of the chest revealed no abnormal findings in the left lung and no pleural effusion in the thoracic cavity,having mottling in the lower lobe of his right lung,and unobstructed bronchial.